Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who achieved greater response with tofacitinib do so regardless of whether ...
Pfizer’s troubled JAK inhibitor Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s higher dose in rheumatoid arthritis. Now, Pfizer is hoping for better results ...
Factors ranging from limited perceived advantage to limited geographic availability have prevented the rheumatoid arthritis (RA) treatment tofacitinib (Xeljanz) from becoming the sort of immediate hit ...
The randomized phase 3b/4 ORAL Surveillance study included 4362 RA patients who were taking methotrexate without adequate control of symptoms. Pfizer announced results from a recently completed ...
Among over 28,000 patients with RA, the crude incidence rate per 1,000 person-years for ILD was lowest with the Janus kinase (JAK) inhibitor tofacitinib, at 1.47 (95% CI 0.54-3.27), reported Matthew C ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Tofacitinib ...
XELJANZ is now approved in more than 20 countries for the treatment of patients with moderately to severely active rheumatoid arthritis who had an inadequate response to existing therapies. Most ...
Pfizer, Inc. PFE announced positive data from a study, which was conducted to demonstrate the efficacy of its Janus kinase inhibitor (JAK) Xeljanz extended release as a monotherapy after withdrawing ...
Patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) were 69% less likely to develop interstitial lung disease (ILD), compared with those treated with adalimumab (Humira), ...
The FDA already has restrictions on the use of Pfizer’s JAK inhibitor Xeljanz at a higher dose because of safety concerns. Now, thanks to new red flags, the agency is weighing a move to tighten those ...
The US Food and Drug Administration approval of tofacitinib (Xeljanz) in November 2012 represents a potential for significant change in the approach to the treatment of rheumatoid arthritis. The US ...
Pfizer Inc. signage is displayed on a monitor on the floor of the New York Stock Exchange (NYSE) in New York, U.S., on Friday, April 22, 2016. The Standard & Poor's 500 Index was little changed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback